Literature DB >> 11455131

Homocysteine and cognitive decline in healthy elderly.

A McCaddon1, P Hudson, G Davies, A Hughes, J H Williams, C Wilkinson.   

Abstract

Serum homocysteine is increased, and correlates inversely with cognitive scores, in Alzheimer's disease (AD), vascular dementia and "age-associated memory impairment". Elevated levels might signal accelerated cognitive decline, although this remains to be established. We therefore repeated Mini-Mental State Examinations, together with additional ADAS-Cog assessments, in 32 healthy elderly individuals to determine whether prior homocysteine levels predicted cognitive changes over a 5-year period. Homocysteine predicted follow-up cognitive scores and rate of decline in cognitive performance independently of age, sex, education, renal function, vitamin B status, smoking and hypertension (p < 0.001). Homocysteine predicted word recall (p = 0.01), orientation (p = 0.02) and constructional praxis scores (p < 0.0001). One subject, with the second highest initial homocysteine, had developed probable AD at follow-up. Fasting total serum homocysteine appears to be an independent predictor of cognitive decline in healthy elderly and exerts a maximal effect on spatial copying skills. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455131     DOI: 10.1159/000051275

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  35 in total

Review 1.  Thoughts on B-vitamins and dementia.

Authors:  Martha Clare Morris; Julie A Schneider; Christine C Tangney
Journal:  J Alzheimers Dis       Date:  2006-08       Impact factor: 4.472

Review 2.  Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy.

Authors:  Bruce Hermann; Michael Seidenberg; Mark Sager; Cynthia Carlsson; Barry Gidal; Raj Sheth; Paul Rutecki; Sanjay Asthana
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

3.  A virtual reality based tool for the assessment of "survey to route" spatial organization ability in elderly population: preliminary data.

Authors:  Francesca Morganti; Sascha Marrakchi; Peter Paul Urban; Giuseppe Alfredo Iannoccari; Giuseppe Riva
Journal:  Cogn Process       Date:  2009-09

Review 4.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

5.  Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum.

Authors:  Natacha Lorius; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Anand Viswanathan; Gad A Marshall
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

Review 6.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

7.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 8.  Psychological interventions for depression in adolescent and adult congenital heart disease.

Authors:  G Y H Lip; D A Lane; T A Millane; M H Tayebjee
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.

Authors:  Christopher B Brady; J Michael Gaziano; Roberta A Cxypoliski; Peter D Guarino; James S Kaufman; Stuart R Warren; Pamela Hartigan; David S Goldfarb; Rex L Jamison
Journal:  Am J Kidney Dis       Date:  2009-07-23       Impact factor: 8.860

10.  Folate, vitamin b(12), and homocysteine as risk factors for cognitive decline in the elderly.

Authors:  Jae-Min Kim; Sung-Wan Kim; Il-Seon Shin; Su-Jin Yang; Woo-Young Park; Sung-Jin Kim; Hee-Young Shin; Jin-Sang Yoon
Journal:  Psychiatry Investig       Date:  2008-03-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.